INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 146 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,400,641 | -26.0% | 2,071,232 | -55.9% | 0.00% | 0.0% |
| Q2 2023 | $51,913,616 | -1.8% | 4,693,817 | +19.3% | 0.00% | 0.0% |
| Q1 2023 | $52,859,392 | +17.5% | 3,935,919 | +8.2% | 0.00% | 0.0% |
| Q4 2022 | $45,001,256 | +19.2% | 3,637,935 | +34.4% | 0.00% | 0.0% |
| Q3 2022 | $37,755,000 | +9.0% | 2,706,414 | +7.9% | 0.00% | 0.0% |
| Q2 2022 | $34,652,000 | -10.9% | 2,509,159 | +5.0% | 0.00% | 0.0% |
| Q1 2022 | $38,873,000 | +21.0% | 2,389,249 | +21.2% | 0.00% | 0.0% |
| Q4 2021 | $32,120,000 | -23.6% | 1,971,759 | -30.3% | 0.00% | 0.0% |
| Q3 2021 | $42,030,000 | -37.6% | 2,830,263 | -16.1% | 0.00% | -50.0% |
| Q2 2021 | $67,363,000 | -11.5% | 3,373,212 | +2.3% | 0.00% | 0.0% |
| Q1 2021 | $76,074,000 | +8.9% | 3,296,117 | +16.5% | 0.00% | 0.0% |
| Q4 2020 | $69,875,000 | -38.5% | 2,828,955 | +3.3% | 0.00% | -50.0% |
| Q3 2020 | $113,593,000 | -4.6% | 2,739,825 | +10.2% | 0.00% | 0.0% |
| Q2 2020 | $119,067,000 | -19.4% | 2,485,217 | +6.0% | 0.00% | -33.3% |
| Q1 2020 | $147,639,000 | -48.1% | 2,344,972 | +2.1% | 0.01% | -40.0% |
| Q4 2019 | $284,574,000 | +86.5% | 2,296,438 | -0.1% | 0.01% | +66.7% |
| Q3 2019 | $152,620,000 | -17.9% | 2,299,880 | -1.6% | 0.01% | -14.3% |
| Q2 2019 | $186,005,000 | -18.6% | 2,337,622 | +14.5% | 0.01% | -22.2% |
| Q1 2019 | $228,413,000 | +12.9% | 2,041,948 | +1.8% | 0.01% | 0.0% |
| Q4 2018 | $202,247,000 | -18.0% | 2,006,622 | +2.7% | 0.01% | -10.0% |
| Q3 2018 | $246,772,000 | +54.9% | 1,952,931 | +2.8% | 0.01% | +42.9% |
| Q2 2018 | $159,336,000 | +79.0% | 1,898,893 | +31.2% | 0.01% | +75.0% |
| Q1 2018 | $89,029,000 | +8.4% | 1,447,135 | +2.9% | 0.00% | 0.0% |
| Q4 2017 | $82,123,000 | +2.2% | 1,405,731 | +1.6% | 0.00% | 0.0% |
| Q3 2017 | $80,330,000 | -50.0% | 1,384,056 | +4.2% | 0.00% | -50.0% |
| Q2 2017 | $160,797,000 | +11.9% | 1,328,133 | +4.5% | 0.01% | +14.3% |
| Q1 2017 | $143,749,000 | +9.0% | 1,270,984 | +4.7% | 0.01% | 0.0% |
| Q4 2016 | $131,905,000 | -32.0% | 1,214,032 | +3.0% | 0.01% | -36.4% |
| Q3 2016 | $194,065,000 | +18.3% | 1,179,083 | +2.6% | 0.01% | +10.0% |
| Q2 2016 | $164,047,000 | +15.6% | 1,149,749 | +4.1% | 0.01% | +11.1% |
| Q1 2016 | $141,897,000 | -12.8% | 1,104,508 | +1.4% | 0.01% | -18.2% |
| Q4 2015 | $162,740,000 | -53.3% | 1,089,655 | -48.2% | 0.01% | -15.4% |
| Q3 2015 | $348,824,000 | +44.3% | 2,103,126 | +110.1% | 0.01% | -18.8% |
| Q2 2015 | $241,674,000 | -10.2% | 1,001,214 | +4.9% | 0.02% | -11.1% |
| Q1 2015 | $269,209,000 | +129.0% | 954,574 | +26.7% | 0.02% | +125.0% |
| Q4 2014 | $117,573,000 | -31.8% | 753,676 | +3.5% | 0.01% | -38.5% |
| Q3 2014 | $172,367,000 | +12.1% | 728,242 | +12.0% | 0.01% | +8.3% |
| Q2 2014 | $153,826,000 | -19.7% | 650,073 | +11.9% | 0.01% | -25.0% |
| Q1 2014 | $191,509,000 | +960.9% | 580,699 | +119.6% | 0.02% | +700.0% |
| Q4 2013 | $18,052,000 | +36.7% | 264,381 | +38.2% | 0.00% | +100.0% |
| Q3 2013 | $13,202,000 | +59.3% | 191,261 | +3.5% | 0.00% | 0.0% |
| Q2 2013 | $8,290,000 | – | 184,866 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |